Brian T Hill, Shuo Ma, Clive S Zent, Andrea M Baran, Danielle S Wallace, Anjali S Advani, Allison M Winter, Jane N Winter, Leo I Gordon, Reem Karmali, Jane L Liesveld, Deborah A Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P Miskin, Michael S Weiss, Jonathan W Friedberg, Paul M Barr
Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton's tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors, including umbralisib, have significant clinical activity in relapsed/refractory CLL, but prolonged exposure is associated with potential toxicities. Due to the synergistic anti-tumor effects of combined PI3K and BCL-2 inhibition, we sought to explore the feasibility of response-adapted, time-limited therapy to optimize disease control while mitigating the risks of prolonged treatment...
October 23, 2023: Blood Advances